Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma (Skin)
First Posted Date
2004-06-16
Last Posted Date
2015-10-02
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
34
Registration Number
NCT00002973
Locations
🇺🇸

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

First Posted Date
2004-06-11
Last Posted Date
2013-07-10
Lead Sponsor
Oncotherapeutics
Registration Number
NCT00085345
Locations
🇺🇸

Comprehensive Blood and Cancer Center, Bakersfield, California, United States

🇺🇸

Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States

🇺🇸

Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States

and more 15 locations

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2004-06-11
Last Posted Date
2019-11-27
Lead Sponsor
Alliance for Clinical Trials in Oncology
Registration Number
NCT00085449
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 21 locations

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

First Posted Date
2004-06-11
Last Posted Date
2014-01-10
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
25
Registration Number
NCT00084695
Locations
🇺🇸

Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Phase 1
Withdrawn
Conditions
Leukemia
Lymphoma
First Posted Date
2004-06-09
Last Posted Date
2013-03-07
Lead Sponsor
Duke University
Registration Number
NCT00003435
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

First Posted Date
2004-06-04
Last Posted Date
2017-11-20
Lead Sponsor
University of Arkansas
Target Recruit Count
97
Registration Number
NCT00083915
Locations
🇺🇸

University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

First Posted Date
2004-06-03
Last Posted Date
2019-10-17
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT00003401
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

First Posted Date
2004-06-03
Last Posted Date
2019-10-17
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
42
Registration Number
NCT00003396
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

First Posted Date
2004-06-03
Last Posted Date
2019-10-17
Lead Sponsor
University of Maryland, Baltimore
Registration Number
NCT00003399
Locations
🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

First Posted Date
2004-05-27
Last Posted Date
2015-11-23
Lead Sponsor
University of Arkansas
Target Recruit Count
668
Registration Number
NCT00083551
Locations
🇺🇸

University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy